Effects of Exercise and GLP-1 Agonism on Muscle Microvascular Perfusion and Insulin Action in Adults With Metabolic Syndrome

Who May Qualify: - Male or female ≥21 and ≤60 years old. - Body mass index \>25 and ≤35 kg/m2 and is weight stable (\<5 kg weight change in the past 6 months). BMI is limited to ≤35 kg/m2 for easier vascular access and cardiac imaging. - Meet 3 of 5 National Cholesterol Education Program Adult Treatment Panel III Metabolic Syndrome criteria: - Increased waist circumference (≥102 cm in men; ≥88 cm in women) - Elevated triglycerides (≥150 mg/dl) - Reduced HDL-cholesterol (\<40mg/dl in men, \<50 mg/dl in women) - High blood pressure (≥130 mmHg systolic or ≥85mmHg diastolic) - Elevated fasting glucose (≥100 mg/dl) - Subject may participate if on the following drugs, provided the drug doses have been stable for at least 3 months. - Ace inhibitor - ARB - HMG CoA reductase inhibitor - Beta blocker - Calcium channel blockers - Alpha-adrenergic antagonist - Statin Who Should NOT Join This Trial: - A diagnosis of any type of diabetes or history of diabetes medication use - Recently active (\>20 min of moderate/high intensity exercise, 2 times/week) - Subjects who are smokers or who have quit smoking \<5 years - Subjects with hypertriglyceridemia (\>400 mg/dl) or hypercholesterolemia (\>260 mg/dl) - Subjects with BP\>160/90 - Subjects with a history of significant metabolic, cardiac, cerebrovascular, hematological, pulmonary, gastrointestinal, liver, renal, or endocrine disease or malignancy - Pregnant (as evidenced by positive pregnancy test) or nursing women - Subjects with contraindications to participation in an exercise training program - Allergic to perflutren - A prior use of Liraglutide Always talk to your doctor about whether this trial is right for you.